| Literature DB >> 35053281 |
Thibaut Barbier1, Alexia Barbry2,3, Jérémy Magand1, Cédric Badiou3, Floriane Davy3, Anne Baudouin4, Yves Queneau1, Oana Dumitrescu2,3, Gérard Lina2,3, Laurent Soulère1.
Abstract
The benzo[b]thiophene nucleus and the acylhydrazone functional group were combined to prepare three new series of compounds for screening against Staphylococcus aureus. The reaction of substituted benzo[b]thiophene-2-carboxylic hydrazide and various aromatic or heteroaromatic aldehydes led to a collection of 26 final products with extensive structural diversification on the aromatic ring and on position 6 of the benzo[b]thiophene nucleus. The screening lead to the identification of eight hits, including (E)-6-chloro-N'-(pyridin-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide (II.b), a non-cytotoxic derivative showing a minimal inhibitory concentration of 4 µg/mL on three S. aureus strains, among which were a reference classical strain and two clinically isolated strains resistant to methicillin and daptomycin, respectively.Entities:
Keywords: MRSA; Staphylococcus aureus; acylhydrazone; antibacterial; benzothiophene
Mesh:
Substances:
Year: 2022 PMID: 35053281 PMCID: PMC8773820 DOI: 10.3390/biom12010131
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1General structure of set I derivatives.
Scheme 1Synthesis of set I derivatives.
Figure 21H NMR spectra of I.a at different temperatures.
Minimum inhibitory concentrations of set I molecules against S. aureus strains.
| Name | Structure | LogP | MIC (µg/mL) | ||
|---|---|---|---|---|---|
| ATCC 29213 a | SF8300 b | ST20171643 c | |||
|
|
| 4.20 | 32 | 64 | 16 |
|
|
| 4.41 | >256 | >256 | >256 |
|
|
| 3.13 | 16 | 16 | 16 |
|
|
| 3.07 | >256 | >256 | >256 |
|
|
| 3.02 | >256 | >256 | >256 |
|
|
| 3.80 | >256 | >256 | ND |
|
|
| 3.83 | >256 | >256 | >256 |
|
|
| 3.64 | >256 | >256 | >256 |
|
|
| 4.98 | 128 | 128 | 128 |
|
|
| 4.47 | >256 | >256 | 128 |
|
|
| 4.24 | >256 | >256 | ND |
|
|
| 4.26 | 64 | 64 | 32 |
|
|
| 3.83 | 256 | >256 | >256 |
|
|
| 4.19 | >256 | >256 | 256 |
|
|
| 4.22 | >256 | >256 | 256 |
|
|
| 2.33 | 64 | 64 | 64 |
a: methicillin-sensitive S. aureus; b: methicillin-resistant S. aureus; c: daptomycin-resistant S. aureus.
Scheme 2Synthesis of compound I.p.
Figure 3General structure of set II derivatives.
Scheme 3Synthesis of set II and III derivatives.
Minimum inhibitory concentrations of set II molecules against S. aureus strains.
| Name | Structure | LogP | MIC (µg/mL) | ||
|---|---|---|---|---|---|
| ATCC 29213 a | SF8300 b | ST20171643 c | |||
|
|
| 4.85 | >256 | >256 | >256 |
|
|
| 3.79 | 4 | 4 | 4 |
|
|
| 4.33 | >256 | >256 | >256 |
|
|
| 3.27 | 32 | 16 | 16 |
a: methicillin-sensitive S. aureus; b: methicillin-resistant S. aureus; c: daptomycin-resistant S. aureus.
Minimum inhibitory concentrations of set III molecules against S. aureus strains.
| Name | Structure | LogP | MIC (µg/mL) | ||
|---|---|---|---|---|---|
| ATCC 29213 a | SF8300 b | ST20171643 c | |||
|
|
| 3.19 | 256 | 64 | 64 |
|
|
| 4.22 | >256 | 256 | 256 |
|
|
| 3.79 | >256 | 256 | 256 |
|
|
| 3.89 | >256 | >256 | >256 |
|
|
| 3.15 | >256 | 256 | 128 |
|
|
| 4.01 | 32 | 8 | 16 |
a: methicillin-sensitive S. aureus; b: methicillin-resistant S. aureus; c: daptomycin-resistant S. aureus.
Scheme 4Synthesis of III.d.
Scheme 5Synthesis of III.e.
Figure 4Effect of II.b on the growth of A549 cells.